About NiKang Therapeutics
NiKang Therapeutics is a company based in Wilmington (United States) founded in 2017 by Zhenhai Gao and Yan Lou.. NiKang Therapeutics has raised $260 million across 3 funding rounds from investors including BlackRock, Citadel and Janus Henderson Investors. The company has 24 employees as of December 31, 2021. NiKang Therapeutics offers products and services including NKT3964 and NKT2152. NiKang Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Wilmington, United States
- Employees 24 as on 31 Dec, 2021
- Founders Zhenhai Gao, Yan Lou
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nikang Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$260 M (USD)
in 3 rounds
-
Latest Funding Round
$200 M (USD), Series C
May 26, 2021
-
Investors
BlackRock
& 22 more
-
Employee Count
24
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NiKang Therapeutics
NiKang Therapeutics offers a comprehensive portfolio of products and services, including NKT3964 and NKT2152. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Orally bioavailable degrader for CDK2 in cancer therapy development.
Drug for hepatocellular carcinoma treatment in clinical trials.
Unlock access to complete
Funding Insights of NiKang Therapeutics
NiKang Therapeutics has successfully raised a total of $260M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $200 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $200.0M
-
First Round
First Round
(01 Jun 2017)
- Investors Count 23
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Series C - NiKang Therapeutics | Valuation | HBM Healthcare Investments , Octagon Capital Advisors | |
| Sep, 2020 | Amount | Series B - NiKang Therapeutics | Valuation | RTW Investments , Lilly Asia Ventures |
|
| Jun, 2017 | Amount | Series A - NiKang Therapeutics | Valuation | CBC Group |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NiKang Therapeutics
NiKang Therapeutics has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Citadel and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences focused VC firm funding companies in the US and Europe
|
Founded Year | Domain | Location | |
|
Investments in healthcare startups are managed by Octagon Capital Advisors.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NiKang Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NiKang Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nikang Therapeutics Comparisons
Competitors of NiKang Therapeutics
NiKang Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nikang Therapeutics
Frequently Asked Questions about NiKang Therapeutics
When was NiKang Therapeutics founded?
NiKang Therapeutics was founded in 2017.
Where is NiKang Therapeutics located?
NiKang Therapeutics is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Who is the current CEO of NiKang Therapeutics?
Zhenhai Gao is the current CEO of NiKang Therapeutics. They have also founded this company.
Is NiKang Therapeutics a funded company?
NiKang Therapeutics is a funded company, having raised a total of $260M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Jun 01, 2017.
How many employees does NiKang Therapeutics have?
As of Dec 31, 2021, the latest employee count at NiKang Therapeutics is 24.
What does NiKang Therapeutics do?
NiKang Therapeutics was established in 2017 and is headquartered in Wilmington, United States. Focus is placed on the creation of small molecule medicines targeting oncology, utilizing structure-based drug design. Research and development efforts are directed toward advancing treatments for various cancers, with operations centered in the biotechnology sector. Key leadership includes co-founders Zhenhai Gao as CEO and Yan Lou as CSO.
Who are the top competitors of NiKang Therapeutics?
NiKang Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does NiKang Therapeutics offer?
NiKang Therapeutics offers NKT3964 and NKT2152.
Who are NiKang Therapeutics's investors?
NiKang Therapeutics has 23 investors. Key investors include BlackRock, Citadel, Janus Henderson Investors, RTW Investments, and RA Capital.